These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 32808736

  • 21. Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy: insights from cardiac magnetic resonance analysis.
    Nakamura T, Iwanaga Y, Yasuda M, Kawamura T, Miyaji Y, Morooka H, Miyazaki S.
    Int J Cardiovasc Imaging; 2016 Apr; 32(4):613-20. PubMed ID: 26589516
    [Abstract] [Full Text] [Related]

  • 22. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography].
    Faber L, Seggewiss H, Fassbender D, Bogunovic N, Strick S, Schmidt HK, Gleichmann U.
    Z Kardiol; 1998 Mar; 87(3):191-201. PubMed ID: 9586154
    [Abstract] [Full Text] [Related]

  • 23. Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy: 18-month follow-up results.
    Oomman A, Ramachandran P, Subramanyan K, Kalarickal MS, Osman MN.
    J Invasive Cardiol; 2001 Jul; 13(7):526-30. PubMed ID: 11435640
    [Abstract] [Full Text] [Related]

  • 24. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound® technology to guide ablation.
    Cooper RM, Shahzad A, Hasleton J, Digiovanni J, Hall MC, Todd DM, Modi S, Stables RH.
    Europace; 2016 Jan; 18(1):113-20. PubMed ID: 26541709
    [Abstract] [Full Text] [Related]

  • 25. [Long-term outcome of patients with hypertrophic obstructive cardiomyopathy post percutaneous transluminal septal ablation].
    Zheng SW, Shi HY, Dai JJ, Chen H, Wu WH, Qiu XB.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr 24; 48(4):294-301. PubMed ID: 32370480
    [Abstract] [Full Text] [Related]

  • 26. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.
    Alam M, Dokainish H, Lakkis N.
    J Interv Cardiol; 2006 Aug 24; 19(4):319-27. PubMed ID: 16881978
    [Abstract] [Full Text] [Related]

  • 27. [Percutaneous transluminal septal myocardial ablation: early results and long-term follow-up].
    Tekieli Ł, Pieniazek P, Podolec P, Tomkiewicz-Pajak L, Płazak W, Musiałek P, Leśniak-Sobelga A, Przewłocki T, Biernacka B, Zmudka K, Tracz W.
    Przegl Lek; 2006 Aug 24; 63(8):628-32. PubMed ID: 17441371
    [Abstract] [Full Text] [Related]

  • 28. Effect of septal ablation on regional diastolic dysfunction and diastolic asynchrony in patients with hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiography.
    Chen S, Duan F, Yuan J, Qiao S, Lv X, Hu F, Yang W, Zhang J, Yang Y.
    Echocardiography; 2013 May 24; 30(5):564-71. PubMed ID: 23305549
    [Abstract] [Full Text] [Related]

  • 29. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy.
    Shelke AB, Menon R, Kapadiya A, Yalagudri S, Saggu D, Nair S, Narasimhan C.
    Indian Heart J; 2016 May 24; 68(5):618-623. PubMed ID: 27773399
    [Abstract] [Full Text] [Related]

  • 30. Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation.
    Malek LA, Chojnowska L, Klopotowski M, Maczynska R, Demkow M, Witkowski A, Kusmierczyk B, Piotrowicz E, Konka M, Dabrowski M, Ruzyllo W.
    Eur J Heart Fail; 2008 Nov 24; 10(11):1123-6. PubMed ID: 18840395
    [Abstract] [Full Text] [Related]

  • 31. Percutaneous transluminal septal myocardial ablation: a novel, nonsurgical treatment for symptomatic hypertrophic cardiomyopathy.
    Kar S, Makkar R.
    Rev Cardiovasc Med; 2001 Nov 24; 2(2):97-102. PubMed ID: 12439386
    [Abstract] [Full Text] [Related]

  • 32. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy.
    Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, Dolney DO, Blackstone EH.
    Ann Thorac Surg; 2008 Jan 24; 85(1):127-33. PubMed ID: 18154797
    [Abstract] [Full Text] [Related]

  • 33. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy.
    Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH, Nagueh SF.
    J Am Coll Cardiol; 2001 Jan 24; 37(1):208-14. PubMed ID: 11153740
    [Abstract] [Full Text] [Related]

  • 34. Successful percutaneous septal alcohol ablation after surgical myectomy.
    Kulić M, Spuzić M, Tahirović E, Sehović S, Mujacić V, Zorman D, Velebit V.
    Bosn J Basic Med Sci; 2010 Aug 24; 10(3):218-22. PubMed ID: 20846128
    [Abstract] [Full Text] [Related]

  • 35. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre.
    Bhagwandeen R, Woo A, Ross J, Wigle ED, Rakowski H, Kwinter J, Eriksson MJ, Schwartz L.
    Can J Cardiol; 2003 Jul 24; 19(8):912-7. PubMed ID: 12876612
    [Abstract] [Full Text] [Related]

  • 36. Long-term clinical and echocardiographic outcomes of extensive septal myectomy for hypertrophic obstructive cardiomyopathy in Chinese patients.
    Yao L, Li L, Lu XJ, Miao YL, Kang XN, Duan FJ.
    Cardiovasc Ultrasound; 2016 May 17; 14(1):18. PubMed ID: 27189485
    [Abstract] [Full Text] [Related]

  • 37. [Non-pharmacologic therapy of hypertrophic obstructive cardiomyopathy--results of therapy based on percutaneous transluminal septal myocardial ablation compared with results of dual-chamber cardiac pacing].
    Krejcí J, Groch L, Meluzín J, Vykypel T, Halámek J, Vitovec J.
    Vnitr Lek; 2006 Apr 17; 52(4):313-20. PubMed ID: 16755987
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of left ventricular myocardial perfusion and function using gated SPECT in patients with hypertrophic obstruction cardiomyopathy following percutaneous transluminal septal myocardial ablation.
    Zhang L, Liu R, Qiao SB, Sun XX, He ZX, Tian YQ.
    Nucl Med Commun; 2014 Jul 17; 35(7):762-6. PubMed ID: 24681766
    [Abstract] [Full Text] [Related]

  • 39. Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography.
    Patel P, Dhillon A, Popovic ZB, Smedira NG, Rizzo J, Thamilarasan M, Agler D, Lytle BW, Lever HM, Desai MY.
    Circ Cardiovasc Imaging; 2015 Jul 17; 8(7):e003132. PubMed ID: 26082555
    [Abstract] [Full Text] [Related]

  • 40. A case of successful percutaneous transluminal septal myocardial ablation for heart failure due to severe left ventricular outflow obstruction with Mönckeberg's arteriosclerosis, manifested after aortic valvular replacement.
    Kato M, Miyahara M, Suzuki H, Uchida F, Nishimura Y, Nishikawa H.
    Cardiovasc Interv Ther; 2015 Jan 17; 30(1):72-7. PubMed ID: 24566833
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.